Ipsen may be a recent entrant into…
Ipsen may be a recent entrant into the antibody-drug conjugate [...]
Ipsen’s oral small molecule…
Ipsen’s oral small molecule failed to reduce the progression of [...]
Venture capital firm Aditum Bio is…
Venture capital firm Aditum Bio is going all-out for a [...]
Merck & Co. is turning down…
Merck & Co. is turning down its option to license [...]
Altimmune has shared an update on…
Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis [...]
Boehringer Ingelheim has turned…
Boehringer Ingelheim has turned down its chance to license Nxera [...]
Longtime Pfizer R&D…
Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big [...]
After a long and strange year,…
After a long and strange year, Belgian biotech Galapagos is [...]
After taking a stab at becoming a…
After taking a stab at becoming a neuroscience biotech, buzzy [...]
Daiichi Sankyo and Merck &…
Daiichi Sankyo and Merck & Co.’s phase 3 program for [...]